Espero BioPharma Announces Tecarfarin Receives FDA Orphan Drug Designation for Patients with End Stage Renal Disease and Atrial Fibrillation
11 mars 2019 08h30 HE
|
Espero BioPharma
JACKSONVILLE, Fla. and IRVINE, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- Espero BioPharma, Inc., a pharmaceutical company focused on the development of therapeutics for unmet needs in thrombosis...
Espero BioPharma Provides Update on the Development of Tecarfarin for the Treatment of Mechanical Heart Valve Patients in China
24 janv. 2019 11h00 HE
|
Espero BioPharma
JACKSONVILLE, Fla. and IRVINE, Calif., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Espero BioPharma, Inc., a pharmaceutical company focused on the development of late-stage drugs for unmet needs in thrombosis...
Espero BioPharma Appoints Lee Golden, M.D., as Chief Medical Officer
09 oct. 2018 09h00 HE
|
Espero Biopharma
JACKSONVILLE, Fla. and IRVINE, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Espero BioPharma, Inc., (“Espero”, or “the Company”), a pharmaceutical company focused on the development of late-stage drugs...
Espero BioPharma to Present at the 2018 BIO International Convention, Wednesday, June 6, 2018
30 mai 2018 09h00 HE
|
Espero Biopharma
JACKSONVILLE, Fla., May 30, 2018 (GLOBE NEWSWIRE) -- Espero BioPharma, Inc., (the “Company”) a biopharmaceutical company focusing on the late-stage development and commercialization of drugs to...
Espero BioPharma to Present at Biotech Showcase on January 9, 2018
03 janv. 2018 08h30 HE
|
Espero Biopharma
JACKSONVILLE, Fla. and IRVINE, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Espero BioPharma, a biopharmaceutical company focusing on the late-stage development and commercialization of drugs to treat...
Espero BioPharma Provides Corporate Update and 2018 Objectives
12 déc. 2017 08h30 HE
|
Espero Biopharma
- Pivotal Phase 3 trial for tecarfarin under FDA-approved Special Protocol Assessment provides clear regulatory pathway to the $8.5 billion U.S. oral anticoagulant market - JACKSONVILLE, Fla. and...